IMNM
Immunome, Inc.
NASDAQ · Healthcare · Biotechnology · US
$26.76
−1.47%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | 6.9M | 9.0M | 14.0M | — |
| Cost of Revenue | 49.9M | 3.0M | — | — | — |
| Gross Profit | (49.9M) | 4.0M | 9.0M | 14.0M | — |
| Operating Expenses | |||||
| R&D Expense | 216.2M | 174.3M | 129.5M | 23.1M | 23.3M |
| SG&A Expense | 54.2M | 43.8M | 33.0M | 19.7M | 13.6M |
| General & Admin Expense | 54.2M | 43.8M | 33.0M | 19.7M | 13.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (49.9M) | — | 152.3M | 80.8M | — |
| Total Operating Expenses | 220.5M | 218.1M | 314.8M | 123.5M | 36.9M |
| Cost and Expenses | 270.5M | 221.1M | 314.8M | 123.5M | 36.9M |
| Operating Income (EBIT) | (270.5M) | (214.1M) | (305.8M) | (109.5M) | (36.9M) |
| Non-Operating | |||||
| Interest Income | 16.1M | 11.7M | 12.8M | 2.7M | 5.0K |
| Interest Expense | — | — | — | — | 5.0K |
| Net Interest Income | 16.1M | 11.7M | 12.8M | 2.7M | — |
| Other Non-Op Income/Expense | 16.1M | 1.7M | 12.8M | 2.7M | 5.0K |
| Non-Operating Income (excl Interest) | (16.1M) | (1.7M) | (152.3M) | (80.8M) | (10.0K) |
| EBT (Pre-Tax Income) | (254.3M) | (212.4M) | (293.0M) | (106.8M) | (36.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (254.3M) | (212.4M) | (293.0M) | (106.8M) | (36.9M) |
| Earnings from Cont. Ops | (254.3M) | (212.4M) | (293.0M) | (106.8M) | (36.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (254.3M) | (212.4M) | (293.0M) | (106.8M) | (37.5M) |
| Per Share | |||||
| Basic EPS | ($2.54) | ($2.43) | ($5.00) | ($5.38) | ($3.09) |
| Diluted EPS | ($2.54) | ($2.43) | ($5.00) | ($5.38) | ($3.09) |
| Revenue Per Share | $0.00 | $0.08 | $0.15 | $0.71 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 113.3M | 87.4M | 58.6M | 19.8M | 12.1M |
| Diluted Shares Outstanding | 113.3M | 87.4M | 58.6M | 19.8M | 12.1M |
| Profitability Metrics | |||||
| EBITDA | (251.2M) | (209.4M) | (151.4M) | (28.0M) | (36.3M) |
| D&A | 3.1M | 3.0M | 2.1M | 728.0K | 631.0K |
| EBIT | (254.3M) | (212.4M) | (153.5M) | (28.7M) | (36.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026